HUE034251T2 - Staphylococcus aureusból származó 5. típusú és 8. típusú kapszuláris szacharidok tisztítása - Google Patents
Staphylococcus aureusból származó 5. típusú és 8. típusú kapszuláris szacharidok tisztítása Download PDFInfo
- Publication number
- HUE034251T2 HUE034251T2 HUE10782040A HUE10782040A HUE034251T2 HU E034251 T2 HUE034251 T2 HU E034251T2 HU E10782040 A HUE10782040 A HU E10782040A HU E10782040 A HUE10782040 A HU E10782040A HU E034251 T2 HUE034251 T2 HU E034251T2
- Authority
- HU
- Hungary
- Prior art keywords
- lys
- ser
- asn
- thr
- asp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- External Artificial Organs (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Claims (2)
- SZABADALMI KifeNVPONTOK; 1, bptdozémotekuíához ka$agá%. 3L mummbM·. szárniáéo & dpbié kapszuláé pöIísxMPIrie él ép löido^6«K?tóka|álsoz |is|«p?k if: «I® Is llpösö :b|ïs®ilfe :p!toctefc wmttmé llpp^^tÉk^Â^ eíolíIMsám, mely efárás iÄlOilkll I köfÄ~ zdfcsk (à) eb ázás k&p&uiâris po!e?ach»rid tisztításét» 5. típusé S «««vwv leitekből, mely 'ttâslmax «gy^ •pest, oie b-beu s kapszuiarb pobszachoriäoi feKzabadOjek u sejtekbe· e xejiek savas kc?.e!êse biudk îîJïoI a sejrek nedves scjtmasäM ibrmâjâbsn vsooak vagy vtzee közegben s/us?.peodálv»:ve»n»kf:is & ffegi|öi p;>! issaebád d moíek idaíömege 2-ls §00 kDa; dd a k*p»;ttVtiiN pofeuouiOuU konjugálásé agy inu Johnok ki kdhu' krigugiíum rí xdiUu,Jt veíwho: # IC) a konjugátum eîkeverése egy hordozámoiekníáboz koojag&H, 5. ííureaxból sxánnazó $ típusú
- 2. Fi járna egy kerdözimátóísMhö^: koeiygétt f. öí^msMÍ származó 8, IfpMu kípzidáfi poliszach&ridot és egy borduzémoíekuláho?. konjugált -S. itt/mtíből százMké I. típusé kapizidáiys pokvacn esdoí toltam izo sor ujpogtm ke-, urnem de · hk 'siivu u\ >x auide k'tohna^i a kőtelke- zôkub ,as y P' k^p«.?rk^i' PO \ubottd tt*> h,-us 8 4 p ^ < < ' vfkV >1 hk x su Oint eg> Se pfsk melyben a fefpszuSéris poifazocharâN fe Fra bad rusk s sojíekbbl a sejtek savas keltése öpatk ahol a fejtek nedves zejinuss.í& íbrutéjábsa vannak vagy vises fcöldgbeg gägtgypeudltvk vaunglg el a tisztítóit poliszsdi&sid mulekukiíínnege 2-0500 kid; (b> a kapszulám prdSszach&nd koujugáte egv b#Âià:idÉb|^Âé^sÂj^#Âtu eis*àihtô*>a gépből; èS lel a kemjugámm elkevetéss egy hordozómtde-kuláboz koniugáit. S .m««sMÍ szúmmxé S. típusú kapszulám polisz&chariddai. J, Az í. vagy 2.. íglttypgs szerinti eijátá\.s gbol p| a savas kezelést eoetsav dkdmadísávd végezzék és/vagy (ü) az eljárás tartalmaz továbbá egy semlegesítési lépést. 4, s V 0 o {get νρ idő* be vt w ^ u vH i.s x s íz > b V'V î» f»' 'Uí U'vitbbo \y k;\'^ ' ttík cemritbgáiásáírn és a poltoebarid^artaimtVteluIteé be gyíy lésére. iS. Äz 1-4. igénypontok bármely *ko szerinti eljárás, ahol a* eljárás a* <a) lépésben tartalmaz továbbá >-«gy lépást a kapszulám poliszáéba* hl DNte&i évvagy ílf Imi IfriésA kszálékérfe, P. -w } -S igenypmuok bm melyike w.ermn elírnák aboi az esjárá\ tsz. tat lépésKa tarmlosa? továbbá Sí- xs kost!? \ t ÜV<K' » 0 '<»*«» ï Î. ! > N K' ' \í >s \ \? ^ 'y ,V> p.-VRi .k Ι',ίΓΗΚ k Ike v V. írt .'SUT ίϊ-, Λ'Ι.ίί dj.rtá·. ! ' M k\X 'Km kk VíXAí \, KV, mK a k4vetkezÁ>ket: |a) egy rimezümsi lépés; I b) egy anhnppré'IS .kromatográfiás lépés; <£> egy géhzürési KxK émYam (d'> egy lépés a polisz-ieharid mméityitésére,. \M ”* t$*H\p""k>k KinnJvíU vMud ehatu-N ahol az φιτΛ u/ v4' lépesbe» t K>dm.\>z»;:.tovabba a következőkéi? > ,¾ I.A·, i <n|ols ie » s>f, o sem· hk, V tiv! (d) úgy xterilMbém lépés. |4, Igénypontok |«gí||p«?|f|8tl eljárás, ahol az epÄ m- (áj MgÄal op kivkt|ezik«t: brialmazié tósmtményi mrdménymo «a> a polis >aeh*mdol es, peptkVghkaa szemnezovkst, ouknek tsissflslps f oBszaobat» eHü* gère vonatkoztatva kevesebb., mini 5 töinegvk pepüéoglikán; és? vagy B|j s pplisMelÄbi és fehérje szenny e/Klést rneiyá|krirsmtnyisége a pnhszaehnrnl össztömeprp: ':-ν0?ί®|^ϋΙΐ^'kw^bh, mmt 5 tömegé fehérje. Uh Az !«>. igénypontok bármelyike szerinti éljÄ.síít: eredményez. amely a pölíszaeiiarkkst és nukteinsav szennyeződést tartalmaz, a^lyatak matmyaságe a puiiszsckarlá Isazbtaagéraasmatedatva kevesebb, trnm '> sümagU «nkfcún«sav Π. Az Mö. igénypontok bármelyike szerinti eljárás, amely tartalmazza továbbá a következe eső-portból vuMemn egy \ axy ;Mls s zna leik' e ,x'myx ivLri'MS.ri wm a ke\znme,-u\ <<gv eb \ a' tigéa; egy «IfB auligéo; egy sdri-2 antigén; egy sdrC antigén; egy sasF antigén; egy·' emp anfigéa; egy sátD antigén; egy spa antigén; egy esaC amidén: egy ttóittl utítíféa; aiy staOOi m*. rigón; egy ísdC antigén; egy HI& antigén; egy staOl ) amigén; egy ísáA antigén; egy isdB antigén- e.> egy sts073 antigén.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25690509P | 2009-10-30 | 2009-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE034251T2 true HUE034251T2 (hu) | 2018-02-28 |
Family
ID=43513776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE10782040A HUE034251T2 (hu) | 2009-10-30 | 2010-11-01 | Staphylococcus aureusból származó 5. típusú és 8. típusú kapszuláris szacharidok tisztítása |
Country Status (22)
Country | Link |
---|---|
US (5) | US9060965B2 (hu) |
EP (2) | EP3199177A1 (hu) |
JP (4) | JP5914344B2 (hu) |
CN (2) | CN109134677A (hu) |
AU (1) | AU2010310919B2 (hu) |
BR (2) | BR112012010223A2 (hu) |
CA (1) | CA2779578A1 (hu) |
CL (1) | CL2012001145A1 (hu) |
CY (1) | CY1118905T1 (hu) |
DK (1) | DK2493498T3 (hu) |
ES (1) | ES2626416T3 (hu) |
HR (1) | HRP20170674T1 (hu) |
HU (1) | HUE034251T2 (hu) |
LT (1) | LT2493498T (hu) |
MX (2) | MX345967B (hu) |
PL (1) | PL2493498T3 (hu) |
PT (1) | PT2493498T (hu) |
RS (1) | RS56000B1 (hu) |
RU (1) | RU2579900C2 (hu) |
SG (1) | SG10201407096RA (hu) |
SI (1) | SI2493498T1 (hu) |
WO (1) | WO2011051917A1 (hu) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180221466A9 (en) * | 2006-06-12 | 2018-08-09 | Glaxosmithkline Biologicals S.A. | Use of alpha-toxin for treating and preventing staphylococcus infections |
TWI469789B (zh) | 2009-06-22 | 2015-01-21 | Wyeth Llc | 金黃色葡萄球菌抗原之免疫原性組合物 |
RU2531234C2 (ru) | 2009-06-22 | 2014-10-20 | ВАЙЕТ ЭлЭлСи | КОНЪЮГАТ ПОЛИСАХАРИД-БЕЛОК ДЛЯ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ЗАЩИТЫ ПРОТИВ ИНФЕКЦИИ Staphylococcus aureus, СПОСОБЫ ПОЛУЧЕНИЯ КОНЪЮГАТА (ВАРИАНТЫ), КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ КОНЪЮГАТ И СПОСОБЫ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ Staphylococcus aureus |
JP2013506651A (ja) * | 2009-09-30 | 2013-02-28 | ノバルティス アーゲー | Staphylococcus.aureus5型および8型莢膜多糖の結合体 |
PT2493498T (pt) * | 2009-10-30 | 2017-05-24 | Glaxosmithkline Biologicals Sa | Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8 |
JP2014507142A (ja) * | 2011-02-08 | 2014-03-27 | インテグレイテッド バイオセラピューティクス,インコーポレイテッド | α溶血素オリゴペプチドを含む免疫原性組成物 |
CN102660602B (zh) * | 2012-04-17 | 2015-03-25 | 江苏康泰生物医学技术有限公司 | 快速纯化细菌荚膜多糖的方法 |
CN110563818A (zh) | 2012-08-31 | 2019-12-13 | 诺华股份有限公司 | 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质 |
GB201310008D0 (en) | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
WO2015010185A1 (en) * | 2013-07-26 | 2015-01-29 | University Of Saskatchewan | Methods for producing salmonella o- antigen capsules, compositions and uses thereof |
BE1023004A1 (fr) | 2014-12-10 | 2016-10-31 | Glaxosmithkline Biologicals Sa | Procede de traitement |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
JP7239509B6 (ja) * | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
US20210070890A1 (en) | 2019-09-06 | 2021-03-11 | Serum Institute Of India Private Limited | Method for obtaining purified bacterial polysaccharides |
US10828360B1 (en) * | 2020-02-04 | 2020-11-10 | OneBioPharma, Inc. | Methods for inhibiting biofilm formation |
WO2021165847A1 (en) | 2020-02-21 | 2021-08-26 | Pfizer Inc. | Purification of saccharides |
JP2023546446A (ja) | 2020-10-22 | 2023-11-02 | ファイザー・インク | 細菌多糖を精製する方法 |
CN112986457B (zh) * | 2021-02-25 | 2022-07-12 | 中国食品药品检定研究院 | HPSEC-MALS法检测多糖并与Sepharose CL-4B法关联的方法 |
CN113234770B (zh) * | 2021-06-15 | 2024-06-14 | 广州知易生物科技有限公司 | 脆弱拟杆菌荚膜多糖a的制备方法 |
WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
CN114957509B (zh) * | 2022-08-01 | 2022-10-21 | 深圳柏垠生物科技有限公司 | 一种可放大的可拉酸纯化方法 |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2166963A (en) * | 1936-11-19 | 1939-07-25 | Sharp & Dohme Inc | Antigenic polysaccharide complex |
FI40107C (fi) * | 1961-05-15 | 1968-10-10 | Parke Davis & Co | Menetelmä uuden stafylokokkiantigeenin valmistamiseksi |
US3269913A (en) * | 1962-05-11 | 1966-08-30 | Parke Davis & Co | Staphylococcal-immunizing products and methods for their production |
GB995338A (en) * | 1963-09-20 | 1965-06-16 | Parke Davis & Co | Polysaccharides and methods for their production |
JPS5452794A (en) | 1977-09-30 | 1979-04-25 | Kousaku Yoshida | Extracting of polysacchride from capusle containing epidermis staphylococus |
US4663160A (en) * | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
US4808700A (en) * | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
US5055455A (en) * | 1988-09-28 | 1991-10-08 | Brigham And Women's Hospital | Capsular polysaccharide adhesin antigen, preparation, purification and use |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
JPH04506662A (ja) | 1989-07-14 | 1992-11-19 | アメリカン・サイアナミド・カンパニー | 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
EP0471177B1 (en) | 1990-08-13 | 1995-10-04 | American Cyanamid Company | Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
FR2682388B1 (fr) * | 1991-10-10 | 1995-06-09 | Pasteur Merieux Serums Vacc | Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal. |
JP4087896B2 (ja) * | 1991-11-22 | 2008-05-21 | ナビ・バイオフアーマシユテイカルズ | スタフィロコッカス・エピダーミジス関連i及びii型表面抗原 |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
US5679654A (en) * | 1994-09-02 | 1997-10-21 | Brigham & Women's Hospital, Inc. | Capsular polysaccharide immunomodulator |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
US6743430B1 (en) * | 1995-03-29 | 2004-06-01 | Richard E. Parizek | Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose |
CZ390297A3 (cs) | 1995-06-07 | 1998-05-13 | Smithkline Beecham Biologicals S. A. | Kombinovaná vakcína |
US6294177B1 (en) * | 1996-09-11 | 2001-09-25 | Nabi | Staphylococcus aureus antigen-containing whole cell vaccine |
US5770208A (en) | 1996-09-11 | 1998-06-23 | Nabi | Staphylococcus aureus B-linked hexosamine antigen |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
CA2284606A1 (en) | 1997-03-26 | 1998-10-01 | Brigham And Women's Hospital, Inc. | Method for generating saccharide fragments |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
BR9813930A (pt) | 1997-11-06 | 2006-12-19 | Chiron Spa | antìgeno neisserial |
KR20010032336A (ko) | 1997-11-21 | 2001-04-16 | 브랑디 빠스깔 | 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도 |
KR100769103B1 (ko) | 1997-11-28 | 2007-10-23 | 세로노 제네틱스 인스티튜트 에스.에이. | 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도 |
WO1999036544A2 (en) | 1998-01-14 | 1999-07-22 | Chiron S.P.A. | Neisseria meningitidis antigens |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
GB9808932D0 (en) * | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
JP5102414B2 (ja) | 1998-05-01 | 2012-12-19 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 髄膜炎菌抗原および組成物 |
US7252828B2 (en) * | 1998-07-15 | 2007-08-07 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
EP1144998A3 (en) | 1998-10-09 | 2002-08-07 | Chiron Corporation | Neisseria genomic sequences and methods of their use |
JP2002529069A (ja) | 1998-11-12 | 2002-09-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クラミジア・ニューモニエのゲノム配列 |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
US6146902A (en) | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
HU228499B1 (en) | 1999-03-19 | 2013-03-28 | Smithkline Beecham Biolog | Streptococcus vaccine |
CA2365914A1 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
US6689567B1 (en) * | 1999-05-28 | 2004-02-10 | University Of Guelph | Method for assaying the function of FlaA1 and WbpM |
CN1416352B (zh) | 2000-01-17 | 2011-05-25 | 启龙股份公司 | 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗 |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
CA2414884A1 (en) | 2000-07-03 | 2002-01-10 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
EP1328543B1 (en) | 2000-10-27 | 2009-08-12 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups a & b |
US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
US6537577B1 (en) * | 2001-06-04 | 2003-03-25 | Bio Medical Development Corporation | Method of prophylaxis for bovine mastitis |
GB2379996B (en) * | 2001-06-05 | 2004-05-19 | Tayside Flow Technologies Ltd | Flow means |
WO2002101026A2 (en) * | 2001-06-11 | 2002-12-19 | Applied Nanosystems B.V. | Methods for binding acma-type protein anchor fusions to cell-wall material of micro-organisms |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
US20040161741A1 (en) | 2001-06-30 | 2004-08-19 | Elazar Rabani | Novel compositions and processes for analyte detection, quantification and amplification |
US20030113350A1 (en) * | 2001-09-19 | 2003-06-19 | Fattom Ali I. | Glycoconjugate vaccines for use in immune-compromised populations |
GB0210128D0 (en) | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
WO2004011027A1 (en) | 2002-07-30 | 2004-02-05 | Baxter International Inc. | Chimeric multivalent polysaccharide conjugate vaccines |
US20060121058A1 (en) * | 2002-08-08 | 2006-06-08 | Children's Medical Center Corporation | Anti-pneumococcal preparations |
EP1597348A4 (en) | 2002-08-26 | 2010-03-31 | Novartis Vaccines & Diagnostic | GENES OF STREPTOCOCCUS PRESERVED OR SPECIFIC |
GB0220198D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Modified saccharides,conjugates thereof and their manufacture |
EP1551357B1 (en) | 2002-09-13 | 2014-07-16 | Novartis Vaccines and Diagnostics, Inc. | Group b streptococcus vaccine |
ES2648046T3 (es) * | 2002-11-12 | 2017-12-28 | The Brigham And Women's Hospital, Inc. | Vacuna de polisacárido para infecciones estafilocócicas |
AU2003290867A1 (en) | 2002-11-12 | 2004-06-03 | The Brigham And Women's Hospital, Inc. | Methods and products for treating staphylococcal infections |
GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
CN1787839B (zh) * | 2003-03-07 | 2011-09-28 | 惠氏控股公司 | 用于抗医院内感染的免疫的多糖-葡萄球菌表面粘附素载体蛋白缀合物 |
DE602004010376T2 (de) | 2003-03-13 | 2008-10-23 | Glaxosmithkline Biologicals S.A. | Verfahren zur reinigung von bakteriellem cytolysin |
JP4764820B2 (ja) * | 2003-06-23 | 2011-09-07 | バクスター・インターナショナル・インコーポレイテッド | ワクチン用担体タンパク質 |
WO2005009378A2 (en) | 2003-07-24 | 2005-02-03 | Merck & Co., Inc. | Polypeptides for inducing a protective immune response against staphylococcus aureus |
CA2532370A1 (en) | 2003-07-24 | 2005-02-03 | Merck & Co., Inc. | Polypeptides for inducing a protective immune response against staphylococcus aureus |
US8048432B2 (en) * | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
ATE460498T1 (de) * | 2003-09-11 | 2010-03-15 | Staat Der Nederlanden Vert Doo | Verfahren zur herstellung eines kapselpolysaccharids zur verwendung in konjugat- impfstoffen |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
EP1725575B1 (en) | 2004-02-18 | 2012-11-28 | Merck Sharp & Dohme Corp. | Polypeptides for inducing a protective immune response against staphylococcus aureus |
EP1725255A4 (en) | 2004-02-27 | 2007-07-11 | Merck & Co Inc | POLYPEPTIDES FOR INDUCING AN IMMUNE RESPONSE PROTECTING AGAINST STAPHYLOCOCCUS AUREUS |
US20050250821A1 (en) * | 2004-04-16 | 2005-11-10 | Vincent Sewalt | Quaternary ammonium compounds in the treatment of water and as antimicrobial wash |
US7842479B2 (en) * | 2004-05-21 | 2010-11-30 | The Board Of Regents Of The University Of Nebraska | Methods for altering acetic acid production and enhancing cell death in bacteria |
JP2008500043A (ja) | 2004-05-25 | 2008-01-10 | メルク エンド カムパニー インコーポレーテッド | 黄色ブドウ球菌に対する感染防御免疫応答を誘導するためのポリペプチド |
GB0413868D0 (en) * | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
CA2579225A1 (en) | 2004-09-17 | 2006-03-30 | Merck & Co., Inc. | Polypeptides for inducing a protective immune response against staphylococcus aureus |
EP2305294B1 (en) | 2004-09-22 | 2015-04-01 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against staphylococcei |
US20060134141A1 (en) | 2004-12-14 | 2006-06-22 | Nabi Biopharmaceuticals | Glycoconjugate vaccines containing peptidoglycan |
US7718182B2 (en) | 2005-01-21 | 2010-05-18 | Merck Sharp & Dohme Corp. | Polypeptides for inducing a protective immune response against Staphylococcus aureus |
GB0502096D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
US20060228368A1 (en) | 2005-04-07 | 2006-10-12 | Nabi Biopharmaceuticals | Method of protecting against staphylococcal infection |
FR2884830A1 (fr) | 2005-04-25 | 2006-10-27 | Sanofi Pasteur Sa | Procede de production de souches de staphylococcus aureus surproductrices |
PT2351578T (pt) * | 2005-06-27 | 2017-04-07 | Glaxosmithkline Biologicals Sa | Processo para o fabrico de vacinas |
EP1937304A2 (en) * | 2005-08-24 | 2008-07-02 | Novartis Vaccines and Diagnostics S.r.l. | Zwitterionization of capsular saccharides |
GB0526038D0 (en) | 2005-12-21 | 2006-02-01 | Glaxosmithkline Biolog Sa | Immunogenic composition |
WO2007084856A2 (en) * | 2006-01-13 | 2007-07-26 | Baxter International Inc. | Method for purifying polysaccharides |
KR101541383B1 (ko) | 2006-03-30 | 2015-08-03 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
AR060188A1 (es) | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Procedimiento de conjugacion |
FR2899110A1 (fr) * | 2006-03-31 | 2007-10-05 | Sanofi Pasteur Sa | Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus |
CN101466406B (zh) | 2006-06-12 | 2012-06-27 | 葛兰素史密斯克蓝生物品公司 | α-毒素在治疗和预防葡萄球菌感染上的用途 |
GB0612854D0 (en) * | 2006-06-28 | 2006-08-09 | Novartis Ag | Saccharide analysis |
WO2008152447A2 (en) | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
WO2008055501A1 (en) * | 2006-11-08 | 2008-05-15 | B-K Medical Aps | Method and apparatus for two-step sterilization |
DE102006062398A1 (de) | 2006-12-20 | 2008-06-26 | Edi (Experimentelle & Diagnostische Immunologie) Gmbh | Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit |
GB0700136D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
CN101679516B (zh) | 2007-05-31 | 2013-11-13 | 默沙东公司 | 靶向金黄色葡萄球菌ORF0657n的抗原结合蛋白 |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
WO2009029831A1 (en) | 2007-08-31 | 2009-03-05 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
EP2254592B1 (en) | 2008-02-28 | 2019-06-05 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
JP5680536B2 (ja) * | 2008-09-17 | 2015-03-04 | ノバルティス アーゲー | 組み合わせgasワクチンおよび治療法 |
AU2009302582A1 (en) * | 2008-10-06 | 2010-04-15 | University Of Chicago | Compositions and methods related to bacterial Eap, Emp, and/or AdsA proteins |
WO2010132833A1 (en) * | 2009-05-14 | 2010-11-18 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
TWI469789B (zh) | 2009-06-22 | 2015-01-21 | Wyeth Llc | 金黃色葡萄球菌抗原之免疫原性組合物 |
RU2531234C2 (ru) * | 2009-06-22 | 2014-10-20 | ВАЙЕТ ЭлЭлСи | КОНЪЮГАТ ПОЛИСАХАРИД-БЕЛОК ДЛЯ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ЗАЩИТЫ ПРОТИВ ИНФЕКЦИИ Staphylococcus aureus, СПОСОБЫ ПОЛУЧЕНИЯ КОНЪЮГАТА (ВАРИАНТЫ), КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ КОНЪЮГАТ И СПОСОБЫ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ Staphylococcus aureus |
GB0913681D0 (en) * | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
JP2013506651A (ja) * | 2009-09-30 | 2013-02-28 | ノバルティス アーゲー | Staphylococcus.aureus5型および8型莢膜多糖の結合体 |
PT2493498T (pt) * | 2009-10-30 | 2017-05-24 | Glaxosmithkline Biologicals Sa | Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8 |
JPWO2011081075A1 (ja) * | 2009-12-28 | 2013-05-09 | キッコーマン株式会社 | 黄色ブドウ球菌抗原の抽出方法、黄色ブドウ球菌抗原の抽出用試薬および黄色ブドウ球菌の判定方法 |
EP2519265B1 (en) * | 2009-12-30 | 2018-11-14 | GlaxoSmithKline Biologicals SA | Polysaccharide immunogens conjugated to e. coli carrier proteins |
CN103037885B (zh) * | 2010-07-02 | 2015-08-26 | 芝加哥大学 | 与蛋白A(SpA)变体相关的组合物和方法 |
GB201310008D0 (en) * | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
CA2932225C (en) | 2013-12-04 | 2023-01-17 | Glycovaxyn Ag | Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli |
US9775872B2 (en) | 2014-08-20 | 2017-10-03 | Professional Compounding Centers Of America | Topical pharmaceutical bases for preventing viral diseases |
WO2018217564A1 (en) * | 2017-05-22 | 2018-11-29 | The Children's Medical Center Corporation | Combined vaccine against mycobacterium tuberculosis |
-
2010
- 2010-11-01 PT PT107820409T patent/PT2493498T/pt unknown
- 2010-11-01 SI SI201031449A patent/SI2493498T1/sl unknown
- 2010-11-01 ES ES10782040.9T patent/ES2626416T3/es active Active
- 2010-11-01 RS RS20170528A patent/RS56000B1/sr unknown
- 2010-11-01 MX MX2015017594A patent/MX345967B/es unknown
- 2010-11-01 MX MX2012004851A patent/MX2012004851A/es unknown
- 2010-11-01 CN CN201810862632.7A patent/CN109134677A/zh active Pending
- 2010-11-01 SG SG10201407096RA patent/SG10201407096RA/en unknown
- 2010-11-01 LT LTEP10782040.9T patent/LT2493498T/lt unknown
- 2010-11-01 PL PL10782040T patent/PL2493498T3/pl unknown
- 2010-11-01 BR BR112012010223A patent/BR112012010223A2/pt not_active Application Discontinuation
- 2010-11-01 EP EP17160320.2A patent/EP3199177A1/en not_active Withdrawn
- 2010-11-01 BR BR122019005883A patent/BR122019005883A8/pt not_active Application Discontinuation
- 2010-11-01 CA CA2779578A patent/CA2779578A1/en not_active Abandoned
- 2010-11-01 CN CN2010800605540A patent/CN102971009A/zh active Pending
- 2010-11-01 AU AU2010310919A patent/AU2010310919B2/en not_active Ceased
- 2010-11-01 HU HUE10782040A patent/HUE034251T2/hu unknown
- 2010-11-01 DK DK10782040.9T patent/DK2493498T3/en active
- 2010-11-01 US US13/504,920 patent/US9060965B2/en active Active
- 2010-11-01 RU RU2012122237/10A patent/RU2579900C2/ru active
- 2010-11-01 EP EP10782040.9A patent/EP2493498B1/en active Active
- 2010-11-01 WO PCT/IB2010/054934 patent/WO2011051917A1/en active Application Filing
- 2010-11-01 JP JP2012536006A patent/JP5914344B2/ja active Active
-
2012
- 2012-04-30 CL CL2012001145A patent/CL2012001145A1/es unknown
-
2015
- 2015-05-15 US US14/714,097 patent/US9441004B2/en not_active Expired - Fee Related
- 2015-12-30 JP JP2015257722A patent/JP2016047852A/ja not_active Withdrawn
-
2016
- 2016-09-07 US US15/258,881 patent/US20160376301A1/en not_active Abandoned
-
2017
- 2017-04-26 CY CY20171100468T patent/CY1118905T1/el unknown
- 2017-05-04 HR HRP20170674TT patent/HRP20170674T1/hr unknown
- 2017-09-01 JP JP2017168223A patent/JP2017206564A/ja not_active Withdrawn
-
2019
- 2019-02-13 US US16/274,822 patent/US11208424B2/en active Active
- 2019-04-05 JP JP2019072625A patent/JP2019104940A/ja not_active Withdrawn
-
2021
- 2021-11-17 US US17/528,426 patent/US20220089627A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11208424B2 (en) | Staphylococcus aureus type 5 capsular saccharides | |
AU2006211049B2 (en) | Purification of streptococcal capsular polysaccharide | |
US10736959B2 (en) | Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides | |
BE1024282B1 (fr) | Compositions immunogènes |